arrow
M

Maja Ludvigsen

Aarhus University Hospital
H指数:16
被引数:996

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Reduced Activity of Soluble Fibroblast Activation Protein (sFAP) Represents a Biomarker of Aggressive Disease in Lymphoid Malignancies

可溶性成纤维细胞活化蛋白(sFAP)活性降低是淋巴性恶性肿瘤中侵袭性疾病的一个生物标志物。

2025-11-210
OAAI
A Danish nationwide population-based cohort study on acute myeloid leukemia with RUNX1::RUNX1T1 – Real-world outcomes and clinicopathological characteristics

一项关于RUNX1::RUNX1T1急性髓系白血病的丹麦全国性基于人群的队列研究——真实世界结局与临床病理特征

2025-10-210
OA
Proteomic Profiling of Limited-Stage Follicular Lymphoma Reveals Differentially Expressed Proteins Linked to Disease Progression Post-Radiation Therapy

局限性滤泡性淋巴瘤的蛋白质组学分析揭示了与放射治疗后疾病进展相关的差异表达蛋白质

2025-09-260
OAAI
Assessing Lipid Nanoparticle RNA Delivery Including CRISPR-Cas9 Based Therapy to Bone Marrow Cells with Emphasis on Leukemic Blasts- a Proof-of-Principle Study

评估脂质纳米颗粒RNA递送(包括基于CRISPR-Cas9的治疗)对骨髓细胞的递送效果,重点关注白血病 blasts——一项概念验证研究

BLOOD
IF23.1
2024-11-050
PRE
Progression of disease within 24 months (POD24) in follicular lymphoma in the rituximab era: incidence, clinicopathological risk factors, and outcome in a population-based Danish cohort
2024-09-300
OAAI
Identification of genetic subtypes in follicular lymphoma
2024-08-071
OAAI
Co-shared genomic alterations within tumors from patients with both myeloproliferative neoplasms and lymphoma
2024-07-250
OAAI
Dual intron-targeted CRISPR-Cas9-mediated disruption of the AML RUNX1-RUNX1T1 fusion gene effectively inhibits proliferation and decreases tumor volume in vitro and in vivo

AML RUNX1-RUNX1T1融合基因的双内含子靶向CRISPR-Cas9-mediated破坏有效抑制体外和体内肿瘤增殖并减小肿瘤体积

LEUKEMIA
IF13.4
2023-07-188
OAAI
IGHV-associated methylation signatures more accurately predict clinical outcomes of chronic lymphocytic leukemia patients than IGHV mutation load
2021-06-035
OAAI